Auspherix Pty Ltd, a Sydney, Australia-based early stage anti-infectives company developing novel antibiotics to treat resistant bacterial disease, secured a further AU$1m in Series A financing.
Spun out from the ithree institute at the University of Technology Sydney (UTS) in 2013 by Ian Charles CSO, Auspherix develops novel antibiotics to treat resistant bacterial diseases. In less than 12 months, it has identified a number of antibacterial compounds with broad spectrum activity against a panel of clinical isolates of antibiotic resistant Gram-positive and Gram-negative bacteria.
Research is being conducted at universities in Australia and the UK, and by UK-based companies Domainex and Evotec.
The company intends to use the funds to progress its antibacterial compounds through development studies and to screen these in vivo models in collaboration with Evotec.